LNA Probe Combination for Rapid rpoB Mutation Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting drug-resistant tuberculosis (DR-TB) are time-consuming, expensive, and lack sensitivity and accuracy, particularly in regions with limited resources, and existing molecular diagnostic technologies are costly and require high expertise.
Innovation Solution
A nucleic acid probe combination using locked nucleic acid (LNA)-modified probes, designed to be fully complementary to mutant sequence segments in the rpoB gene, enhances sensitivity and accuracy for detecting rifampicin resistance in Mycobacterium tuberculosis, allowing for simultaneous detection of multiple mutations in a single reaction tube.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional culture-based drug sensitivity testing is used, then resistance levels to first-line and second-line drugs can be detected simultaneously, but the testing time is too long (about 1 month)
Solution Approach 1:
The patent replaces the traditional culture-based mechanical/biological system with a molecular diagnostic system using LNA-modified probes and PCR amplification. This substitution enables detection within hours rather than months, resolving the time-accuracy contradiction by using biochemical amplification and specific probe hybridization to achieve both speed and precision.
Solution Approach 2:
The patent changes the detection parameter from measuring bacterial growth inhibition (culture method) to detecting specific genetic mutations (molecular method). By targeting the rpoB gene mutations directly through LNA-probe hybridization, the system achieves rapid detection while maintaining accuracy in identifying resistance patterns.
2Loss of time
If rapid molecular diagnostic testing is used, then detection time is shortened to within one day, but the cost is high and expertise requirements are increased
Solution Approach 1:
The patent employs disposable LNA-modified probe cartridges or reagent strips that can be pre-prepared and used in simple PCR devices. This approach reduces the need for expensive specialized equipment and trained personnel, making rapid molecular testing affordable and accessible in resource-limited settings while maintaining detection speed.
Solution Approach 2:
The LNA-modified probes are designed to automatically distinguish mutant from wild-type sequences through differential hybridization and fluorescence signals, reducing the need for expert interpretation. The system performs self-diagnosis by generating clear positive/negative results based on probe binding, minimizing the need for highly trained personnel.
3Measurement precision
If LNA-modified probes are used, then detection sensitivity and accuracy are improved, but the probe complexity and manufacturing cost increase
Solution Approach 1:
The patent applies LNA modifications only at specific critical positions within the probe sequence (typically 3-5 LNA bases centered on the mutation site) rather than throughout the entire probe. This localized modification approach maintains high detection sensitivity and specificity while reducing manufacturing complexity and cost compared to fully modified probes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The LNA-modified probes significantly improve detection sensitivity and accuracy, reducing the time required for results and making the test more affordable and accessible, particularly in economically underdeveloped regions.
Implementation Method 1
each of the plurality of probes is completely complementary to one of mutant sequence segments in the drug resistance-determining region of rpoB gene
Implementation Method 2
at least one of the plurality of probes has a locked nucleic acid (LNA) modification
Data Source
AI summary
A nucleic acid probe combination for detecting rifampicin resistance gene mutations in Mycobacterium tuberculosis, including: a plurality of probes configured for nucleic acid amplification reactions, wherein each of the plurality of probes is completely complementary to one of mutant sequence segments in the drug resistance-determining region of rpoB gene, and at least one of the plurality of probes has a locked nucleic acid (LNA) modification.